BIAF bioAffinity Technologies, Inc.
bioAffinity Technologies (BIAF) news
bioAffinity Technologies, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BIAF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest bioAffinity Technologies news
We have not published a story on bioAffinity Technologies yet. When there is news, it will appear here.
bioAffinity Technologies annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.4 million | $1.5 million |
| Net income (loss) | -$14.9 million | -$9.0 million |
| Cash from operations | -$9.3 million | -$7.3 million |
| Cash and equivalents | $6.4 million | $1.1 million |
Questions about bioAffinity Technologies
What is the ticker symbol of bioAffinity Technologies?
bioAffinity Technologies, Inc. trades under the ticker BIAF on NASDAQ.
Where is bioAffinity Technologies listed?
bioAffinity Technologies, Inc. is listed on NASDAQ.
Which country or territory is bioAffinity Technologies listed under?
Our directory records bioAffinity Technologies, Inc. under United States.
Does aibio.space cover bioAffinity Technologies?
aibio.space lists bioAffinity Technologies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is bioAffinity Technologies profitable?
bioAffinity Technologies, Inc. reported a net loss of $14.9 million for the fiscal year ended Dec 31, 2025, and used $9.3 million of cash in operations, per its annual report to the SEC.
How much does bioAffinity Technologies spend on research and development?
$1.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does bioAffinity Technologies have?
$2.4 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: bioAffinity Technologies
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Financings
Reported a financing. SEC Form S-1. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Stock chart
Listing details
- Company
- bioAffinity Technologies, Inc.
- Ticker
- BIAF
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio